Alere (ALR) Getting Favorable Media Coverage, Analysis Shows

News coverage about Alere (NYSE:ALR) has trended positive this week, according to Accern. Accern scores the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Alere earned a daily sentiment score of 0.25 on Accern’s scale. Accern also gave news articles about the medical research company an impact score of 45.4576825559389 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

A number of analysts recently commented on ALR shares. Zacks Investment Research downgraded Alere from a “hold” rating to a “sell” rating in a research report on Thursday, August 17th. Canaccord Genuity reaffirmed a “hold” rating and set a $51.00 price target on shares of Alere in a research report on Tuesday, September 19th. Finally, BidaskClub downgraded Alere from a “hold” rating to a “sell” rating in a research report on Wednesday, August 9th. One investment analyst has rated the stock with a sell rating and five have assigned a hold rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $51.00.

Shares of Alere (NYSE ALR) remained flat at $$50.99 on Monday. 1,218,600 shares of the company traded hands, compared to its average volume of 1,525,780. Alere has a fifty-two week low of $34.41 and a fifty-two week high of $51.00. The company has a current ratio of 2.04, a quick ratio of 1.54 and a debt-to-equity ratio of 2.43.

TRADEMARK VIOLATION WARNING: This story was posted by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this story on another publication, it was copied illegally and reposted in violation of US and international copyright legislation. The legal version of this story can be read at

Alere Company Profile

Alere Inc is a provider of health information through diagnostic tests. The Company’s segments include professional diagnostics, consumer diagnostics, and corporate and other. The professional diagnostics segment includes an array of diagnostic test products and other in vitro diagnostic tests marketed to medical professionals and laboratories for detection of diseases and conditions within its areas of focus.

Insider Buying and Selling by Quarter for Alere (NYSE:ALR)

Receive News & Ratings for Alere Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alere Inc and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply